Citations

Showing 10 of 108135 citations.

Chemotherapy‐induced anaphylaxis and fatal anaphylaxis in the United States: Incidence and risk factors
Bojanini, Leyla , Morgenstern‐Kaplan, Dan , Carrillo‐Martin, Ismael, Vanegas, Yenny Alejandra Moreno, Cuervo‐Pardo, Lyda , Zwiener, Ricardo , Vanegas, Yenny Moreno , Gonzalez‐Estrada, Alexei

Mayo Clinic

Clinical & Experimental Allergy | September 4, 2021 | Volume: 51 | Issue: 11 | Pages: 1514-1518

10.1111/cea.14011 | PMID 34480372 Get It

UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review
Shaukat, Farah, Hart, Melissa, Bansal, Pankaj , Burns, Timothy, Bansal, Pankaj , Hart, Melissa, Burns, Timothy Francis

Mayo Clinic

Modern Rheumatology Case Reports | September 4, 2021 | Volume: 6 | Issue: 1 | Pages: 134-139

10.1093/mrcr/rxab021 | PMID 34480172 Get It

ABSTRACT Vacuoles, E1 enzyme, X linked, autoinflammatory, somatic (VEXAS) syndrome is a recently described X-linked autoinflammatory condition associated with somatic mutation of the ubiquitin-like modifier activating enzyme 1 (UBA1) gene. It often coexists with myelodysplastic syndrome, which can occur due to DNA (cytosine-5)-methyltransferase 3A (DNMT3A) mutation. These patients, predominantly males, present after the fifth decade of life with unique systemic inflammatory clinical features and have haematological abnormalities and vacuolated precursor cells on bone marrow pathology. Here we describe a unique case of VEXAS syndrome in a patient harbouring DNMT3A gene mutation with coexisting UBA1 mutation with a review of literature.
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
Neelapu, Sattva S. , Bartlett, Nancy L. , Lekakis, Lazaros J. , Miklos, David B. , Jacobson, Caron A. , Braunschweig, Ira , Oluwole, Olalekan O. , Siddiqi, Tanya , Lin, Yi , Crump, Michael , Neste, Eric Van Den , Farooq, Umar , Navale, Lynn, DePuy, Venita, Gisselbrecht, Christian , Bartlett, Nancy L , Miklos, David B , Oluwole, Olalekan O , Siddiqi, Tanya , Farooq, Umar , Lin, Yi , Locke, Frederick L. , Reagan, Patrick Michael , Kuruvilla, John , Kim, Jaeyeon

Mayo Clinic

Blood Advances | September 3, 2021 | Volume: 5 | Issue: 20 | Pages: 4149-4155

10.1182/bloodadvances.2020003848 | PMID 34478487 Get It

Abstract The SCHOLAR-1 international retrospective study highlighted poor clinical outcomes and survival among patients with refractory large B-cell lymphoma (LBCL) treated with conventional chemotherapy. Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, demonstrated durable responses in patients with refractory LBCL in the pivotal phase 1/2 ZUMA-1 study (NCT02348216). Here, we compared SCHOLAR-1 with the 2-year outcomes of ZUMA-1. Prior to comparison of clinical outcomes, propensity scoring (based on a broad set of prognostic covariates) was used to create balance between ZUMA-1 and SCHOLAR-1 patients. In the pivotal phase 2 portion of ZUMA-1, 101 patients received axi-cel and were evaluable for response and survival. In SCHOLAR-1, 434 and 424 patients were evaluable for response and survival, respectively. ZUMA-1 patients were more heavily pretreated than were SCHOLAR-1 patients. The median follow-up was 27.1 months in ZUMA-1. The objective response rate (ORR) and complete response rate were 83% and 54% in ZUMA-1 vs 34% and 12% in SCHOLAR-1, respectively. The 2-year survival rate was 54% in ZUMA-1 and 20% in SCHOLAR-1, and a 73% reduction in the risk of death was observed in ZUMA-1 vs SCHOLAR-1. These results were consistent with those of an additional standardization analysis in which strata were limited to 2 prognostic factors (refractory categorization and presence/absence of stem cell transplant after refractoriness to chemotherapy) to conserve sample size. Despite the limitations of a nonrandomized analysis, these results indicate that axi-cel produces durable responses and a substantial survival benefit vs non–CAR T-cell salvage regimens for patients with refractory LBCL.
Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
Morland, Kellie , Raina, Amresh, Nails, Abigail, Classi, Peter, Etschmaier, Martine, Frantz, Robert P.

Mayo Clinic

Pulmonary Circulation | September 3, 2021 | Volume: 11 | Issue: 4 | Pages: 1-7

10.1177/20458940211046761 | PMID 35024138 Get It

While parenteral prostacyclin (pPCY) therapy, delivered either subcutaneously or intravenously, is recommended for pulmonary arterial hypertension patients with severe or rapidly developing disease, some patients refuse this treatment. This study aimed to understand, directly from patients with pulmonary arterial hypertension, why pPCY was refused and, in some cases, later accepted. Interviews were conducted with 25 pulmonary arterial hypertension patients who previously refused pPCY therapy (Group A: Refused/Never initiated (n = 9) and Group B: Refused/Initiated (n = 16)). Patients in both groups believed that pPCY could improve their symptoms, slow disease progression, and provide them a greater ability to perform activities. Reasons for refusal included concern over side effects and the perceived limitations of pPCY on daily activities. Group A perceived their decision as a balance between quality of life and prolonging life and most acknowledged they would reconsider pPCY if other treatment options were exhausted. Group B cited they initiated therapy due to a worsening of symptoms, disease progression, to improve quality of life, to be there for their family, or a desire to live. Following initiation, Group B indicated their experience met expectations with reduced symptoms, slowed disease progression, and perception of improved survival; concerns related to pPCY were described as manageable. Given the efficacy of pPCY therapy, clinicians should apply knowledge of these findings in clinical practice. Patients noted improvements to parenteral pump technologies to include smaller size, water resistance, and implantability may increase their acceptance of this modality. Development efforts should focus on technologies that increase the acceptance of pPCY when indicated.
First manic episode following COVID‐19 infection
Park, Jin Hong , Kummerlowe, Megan N. , Gardea‐Resendez, Manuel , Núñez, Nicolás A. , Almorsy, Ammar , Frye, Mark A. , Kummerlowe, Megan, Gardea-Resendez, Manuel

Mayo Clinic

Bipolar Disorders | September 3, 2021 | Volume: 23 | Issue: 8 | Pages: 847-849

10.1111/bdi.13123 | PMID 34477297 Get It

Designed architectural proteins that tune DNA looping in bacteria
Tse, David, Becker, Nicole A. , Young, Robert T. , Peters, Justin P. , Schwab, Tanya L., Maher, L. James , Tse, David H, III, Louis James Maher , Olson, Wilma K. , Clark, Karl J.

Mayo Clinic

Nucleic Acids Research | September 3, 2021 | Volume: 49 | Issue: 18 | Pages: 10382-10396

10.1093/nar/gkab759 | PMID 34478548 Get It

Abstract Architectural proteins alter the shape of DNA. Some distort the double helix by introducing sharp kinks. This can serve to relieve strain in tightly-bent DNA structures. Here, we design and test artificial architectural proteins based on a sequence-specific Transcription Activator-like Effector (TALE) protein, either alone or fused to a eukaryotic high mobility group B (HMGB) DNA-bending domain. We hypothesized that TALE protein binding would stiffen DNA to bending and twisting, acting as an architectural protein that antagonizes the formation of small DNA loops. In contrast, fusion to an HMGB domain was hypothesized to generate a targeted DNA-bending architectural protein that facilitates DNA looping. We provide evidence from Escherichia coli Lac repressor gene regulatory loops supporting these hypotheses in living bacteria. Both data fitting to a thermodynamic DNA looping model and sophisticated molecular modeling support the interpretation of these results. We find that TALE protein binding inhibits looping by stiffening DNA to bending and twisting, while the Nhp6A domain enhances looping by bending DNA without introducing twisting flexibility. Our work illustrates artificial approaches to sculpt DNA geometry with functional consequences. Similar approaches may be applicable to tune the stability of small DNA loops in eukaryotes.
Exploring the relationship between neck flexion and neck problems in occupational populations: a systematic review of the literature
Tetteh, Emmanuel , Sarker, Pramiti , Mirka, Gary A. , Norasi, Hamid , Tetteh, Emmanuel , Hallbeck, M Susan , Hallbeck, M. Susan

Mayo Clinic

Ergonomics | September 3, 2021 | Volume: 65 | Issue: 4 | Pages: 587-603

10.1080/00140139.2021.1976847 | PMID 34477048 Get It

Coronary Microcirculatory Dysfunction and Acute Cellular Rejection After Heart Transplantation
Lee, Joo Myung , Choi, Ki Hong, Choi, Jin‐Oh , Shin, Doosup , Park, Yoonjee , Kim, Juwon, Lee, Seung Hun , Kim, Darae, Yang, Jeong Hoon, Cho, Yang Hyun, Sung, Kiick, Choi, Ji Yeon, Park, Meesoon, Kim, Jung-Sun, Park, Taek Kyu, Gwon, Hyeon-Cheol , Oh, Jae K., Jeon, Eun-Seok, Song, Young Bin , Hahn, Joo‐Yong , Choi, Seung-Hyuk , Gwon, Hyeon-Cheol , Shin, Doosup , Lee, Joo Myung , Choi, Ki Hong, Choi, Jin-Oh , Park, Yoonjee , Kim, Juwon, Lee, Seung Hun , Kim, Darae, Yang, Jeong Hoon, Cho, Yang Hyun, Sung, Kiick, Choi, Ji Yeon, Park, Meesoon, Kim, Jung-Sun, Park, Taek Kyu, Oh, Jae K., Jeon, Eun-Seok

Mayo Clinic

Circulation | September 3, 2021 | Volume: 144 | Issue: 18 | Pages: 1459-1472

10.1161/circulationaha.121.056158 | PMID 34474597 Get It

Background: Acute cellular rejection is a major determinant of mortality and retransplantation after heart transplantation. We sought to evaluate the prognostic implications of coronary microcirculatory dysfunction assessed by index of microcirculatory resistance (IMR) for the risk of acute cellular rejection after heart transplantation. Methods: The present study prospectively enrolled 154 heart transplant recipients who underwent scheduled coronary angiography and invasive coronary physiological assessment 1 month after transplantation. IMR is microcirculatory resistance under maximal hyperemia. By measuring hyperemic mean transit time using 3 injections (4 mL each) of room-temperature saline under maximal hyperemia, IMR was calculated as hyperemic distal coronary pressure×hyperemic mean transit time. The primary end point was biopsy-proven acute cellular rejection of grade ≥2R during 2 years of follow-up after transplantation and was compared by using multivariable Cox proportional hazards regression according to IMR. The incremental prognostic value of IMR, in addition to the model with clinical factors, was evaluated by comparison of C-index, net reclassification index, and integrated discrimination index. Results: The mean age of recipients was 51.2±13.1 years (81.2% male), and the cumulative incidence of acute cellular rejection was 19.0% at 2 years. Patients with acute cellular rejection had significantly higher IMR values at 1 month than those without acute cellular rejection (23.1±8.6 versus 16.8±11.1, P =0.002). IMR was significantly associated with the risk of acute cellular rejection (per 5-U increase: adjusted hazard ratio, 1.18 [95% CI, 1.04–1.34], P =0.011) and the optimal cutoff value of IMR to predict acute cellular rejection was 15. Patients with IMR≥15 showed significantly higher risk of acute cellular rejection than those with IMR<15 (34.4% versus 3.8%; adjusted hazard ratio, 15.3 [95% CI 3.6–65.7], P <0.001). Addition of IMR to clinical variables showed significantly higher discriminant and reclassification ability for risk of acute cellular rejection (C-index 0.87 versus 0.74, P <0.001; net reclassification index 1.05, P <0.001; integrated discrimination index 0.20, P <0.001). Conclusions: Coronary microcirculatory dysfunction assessed by IMR measured early after heart transplantation showed significant association with the risk of acute cellular rejection. In addition to surveillance endomyocardial biopsy, early stratification using IMR could be a clinically useful tool to identify patients at higher risk of future acute cellular rejection after heart transplantation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02798731.
Utility of Intracardiac Echocardiography in the Early Experience of Transcatheter Edge to Edge Tricuspid Valve Repair
Eleid, Mackram F. , Alkhouli, Mohamad , Thaden, Jeremy J. , Zahr, Firas , Guerrero, Mayra , Reeder, Guy S., Rihal, Charanjit S. , Guerrero, Mayra E , Alkhouli, Mohamad , Chadderdon, Scott , Rihal, Charanjit S.

Mayo Clinic

Circulation: Cardiovascular Interventions | September 3, 2021 | Volume: 14 | Issue: 10 | Pages: No page available

10.1161/circinterventions.121.011118 | PMID 34474586 Get It

Background: Tricuspid edge to edge repair (TEER) is a novel treatment for severe tricuspid regurgitation and is highly dependent on intraprocedural image quality. To date, transesophageal echocardiography (TEE) has been the primary imaging modality used to guide TEER. The role of intracardiac echocardiography (ICE) has not been assessed. The objective of this study was to describe the use and role of 2-dimensional ICE in the early experience of TEER. Methods: Consecutive patients undergoing TEER (with or without concomitant mitral repair) with off-label use of MitraClip (Abbott, Santa Clara, CA) were included in the study. Utilization of 2-dimensional ICE in comparison with TEE imaging were collected in each procedure through retrospective review of the procedural reports and images. Results: Of 42 TEER cases, ICE was used in 15 (36%) and concomitant mitral repair was performed in 37 (86%). ICE was increasingly used over time for TEER. ICE was able to visualize the tricuspid leaflets with high resolution and provided superior leaflet visualization to TEE in 40% of cases where it was used. Patients treated with ICE guidance tended to have a greater baseline severity of tricuspid regurgitation compared with patients treated with TEE guidance alone (8/15 [53%] massive or greater tricuspid regurgitation versus 6/27 [22%]; P =0.09). Degree of tricuspid regurgitation reduction was similar with TEE alone versus ICE plus TEE guidance (1.9±1.0 versus 2.1±1.1 grade reduction, P =0.28). Conclusions: ICE was increasingly used in the early experience of TEER over time. ICE facilitates leaflet visualization for grasping and is a useful adjunct to TEE during TEER.
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma
Chim, Chor Sang , Kumar, Shaji , Wong, Vincent Kai Chung, Ngai, Cheong , Kwong, Yok‐Lam , Chim, Chor Sang

Mayo Clinic

Hematology | September 3, 2021 | Volume: 26 | Issue: 1 | Pages: 652-655

10.1080/16078454.2021.1965737 | PMID 34474661 Get It